UroGen Pharma Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from UroGen Pharma Ltd.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 95% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 71% in 3 years, but profit fell: $96 less profit per $100 of extra sales. Lower than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-431.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 95% of Healthcare companies in United States.
Cash Locked Ratio
$34For every $100 of sales, $34 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $18 tied up three years earlier.
More money tied up than 74% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$96Sales grew 71% in 3 years, but profit fell: $96 less profit per $100 of extra sales.
Lower than 86% of Healthcare companies in United States.
Asset Productivity Ratio
+71% / +48%In 3 years sales changed by +71% while total assets changed by +48%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Lower than 68% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
UroGen Pharma Ltd. made a loss over the last year. UroGen Pharma Ltd. owes $1.52 for every $1 it owns. UroGen Pharma Ltd. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossUroGen Pharma Ltd. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-12.98UroGen Pharma Ltd.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1.7 BThe total market value of all of UroGen Pharma Ltd.'s shares at today's price (share price × number of shares), larger than 72% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeUroGen Pharma Ltd.'s net worth is negative ($132 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.52×UroGen Pharma Ltd. owes $1.52 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Dividend yield
NoneUroGen Pharma Ltd. does not currently pay a dividend.
Revenue growth
+21%Revenue rose 21% in the year to Dec 2025, and grew 19% a year on average over 3 years.
Profit growth
LossUroGen Pharma Ltd. made a loss in each of the last two years.
Profit margin
-139.8%UroGen Pharma Ltd. lost $140 for every $100 of revenue.
Interest cover
Not coveredUroGen Pharma Ltd.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtUroGen Pharma Ltd. had $8 M more debt than cash (net debt) at Dec 2025.
Questions
How much does UroGen Pharma Ltd. owe compared with what it owns?
UroGen Pharma Ltd. owes $1.52 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Does UroGen Pharma Ltd. pay a dividend?
No. UroGen Pharma Ltd. does not currently pay a dividend.
Is UroGen Pharma Ltd.'s revenue growing?
Revenue rose 21% in the year to Dec 2025, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.